You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: November 28, 2023

SEIZALAM Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Seizalam patents expire, and what generic alternatives are available?

Seizalam is a drug marketed by MMT and is included in one NDA.

The generic ingredient in SEIZALAM is midazolam hydrochloride. There are nine drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the midazolam hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Seizalam

A generic version of SEIZALAM was approved as midazolam hydrochloride by FRESENIUS KABI USA on June 20th, 2000.

  Try a Trial

Summary for SEIZALAM
Drug patent expirations by year for SEIZALAM
Recent Clinical Trials for SEIZALAM

Identify potential brand extensions & 505(b)(2) entrants

Joint Project Management Office for Chemical, Biological, Radiological, and Nuclear MedicalPhase 1
Rafa LaboratoriesPhase 1
Ology BioservicesPhase 1

See all SEIZALAM clinical trials

Pharmacology for SEIZALAM
Drug ClassBenzodiazepine
Anatomical Therapeutic Chemical (ATC) Classes for SEIZALAM

US Patents and Regulatory Information for SEIZALAM

SEIZALAM is protected by zero US patents and one FDA Regulatory Exclusivity.

FDA Regulatory Exclusivity protecting SEIZALAM

Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mmt SEIZALAM midazolam hydrochloride SOLUTION;INTRAMUSCULAR 209566-001 Sep 14, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.